Carboplatin
Top View
- Evaluation of Carboplatin Pharmacokinetics in the Absence and Presence of Paclitaxel’
- Chapter 12: Pharmacokinetics of Chemotherapeutic Agents in Kidney Disease
- Cyclophosphamide and Carboplatin and Selective Consolidation in Advanced Seminoma
- CARBOPLATIN & ETOPOSIDE (CE) for SCLC
- Your Intravenous (IV) Carboplatin and Paclitaxel Chemotherapy Schedule
- Small Cell Lung Cancer Treatment Regimens
- HOPA News Volume 10, Issue 1
- Targeting the Human 80S Ribosome in Cancer: from Structure to Function and Drug Design for Innovative Adjuvant Therapeutic Strategies
- Regimen Reference Order Pegylated Liposomal Doxorubicin + Carboplatin
- Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin As the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
- Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
- Comparison of the Efficacy of Carboplatin, Oxaliplatin and Cisplatin, With
- Computationally Predicting Clinical Drug Combination Efficacy With
- Arsenoplatins Vs. Combination of Platinum Drugs and Arsenic Trioxide
- Pembrolizumab + Paclitaxel + Carboplatin
- Carboplatin (AUC5)-Liposomal Doxorubicin (Caelx) Ver 1
- Ovarian Cancer Treatment Regimens
- BC Cancer Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum